Pretreatment with erythropoietin attenuates the neurological injury after spinal cord ischemia

Spinal Cord. 2012 Mar;50(3):208-12. doi: 10.1038/sc.2011.136. Epub 2011 Nov 29.

Abstract

Study design: Experimental study.

Objectives: To investigate the effect of erythropoietin (EPO) pretreatment on spinal cord ischemic injury.

Setting: Experimental Research Center at Seoul National University Bundang Hospital, Korea.

Methods: Rats were treated with either 1000 IU kg(-1) of EPO (EPO group, n=8) or saline (control group, n=8) 24 h before ischemia. Spinal cord ischemia was induced using a balloon-tipped catheter placed on the proximal descending aorta in the control group and the EPO group, but not in the sham group (n=8). Neurological function was assessed using the motor deficit index (MDI; 0=normal, 6=complete paralysis) until 7 days after reperfusion, and histological examination of spinal cord was performed.

Results: At the first day after reperfusion, the EPO group demonstrated a significantly lower MDI compared with the control group (2.0 (0.3-2.0) vs 4.0 (3.0-4.8), median (interquartile range); EPO group vs control group, respectively; P=0.002). This trend was sustained until 7 days after reperfusion (1.0 (1.0-1.8) vs 4.5 (3.3-5.0); EPO group vs control group, respectively; P=0.001), and more normal motor neurons (29.9±3.1 vs 21.4±3.4, mean±s.d.; EPO group vs control group, respectively; P<0.001) were observed. However, compared with the sham group, the EPO group displayed a significantly higher MDI (0.0, sham group) and fewer intact motor neurons (37.8±5.5, sham group; P<0.001, sham vs control group).

Conclusion: Pretreatment with EPO significantly attenuates neurological injury following spinal cord ischemia, although it cannot completely abolish the ischemic injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Erythropoietin / genetics
  • Erythropoietin / therapeutic use*
  • Male
  • Motor Neurons / metabolism
  • Motor Neurons / pathology
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / therapeutic use
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Spinal Cord Ischemia / pathology
  • Spinal Cord Ischemia / prevention & control*

Substances

  • Neuroprotective Agents
  • Recombinant Proteins
  • Erythropoietin